New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - captopril 5.5 mg/ml (includes 10% excess);  ;  ; captopril 5.5 mg/ml - oral solution - 5 mg/ml - active: captopril 5.5 mg/ml (includes 10% excess)     excipient: citric acid disodium edetate dihydrate hydrochloric acid purified water sodium benzoate sodium citrate dihydrate sodium hydroxide active: captopril 5.5 mg/ml excipient: citric acid disodium edetate dihydrate hydrochloric acid purified water sodium benzoate sodium citrate dihydrate sodium hydroxide - capoten (captopril) is indicated for the treatment of hypertension. in using capoten, consideration should be given to the risk of neutropenia/agranulocytosis. capoten is effective alone and in combination with other antihypertensive agents, especially thiazide-type diuretics. the blood pressure lowering effects of captopril and thiazides are approximately additive.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - fosinopril sodium,hydrochlorothiazide -

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - lisinopril dihydrate, quantity: 21.78 mg - tablet - excipient ingredients: croscarmellose sodium; mannitol; maize starch; magnesium stearate; iron oxide red; calcium hydrogen phosphate dihydrate - 1.hypertension: lisinopril is indicated for the treatment of hypertension. it may be used alone or concomitantly with other classes of antihypertensive agents. sufficient data have not been provided to support the use of lisinopril in severe hypertension or renovascular hypertension. 2. congestive heart failure: lisinopril is also indicated for the treatment of heart failure. in such patients, it is recommended that lisinopril be administered together with a diuretic. 3. acute myocardial infarction: lisinopril is indicated for the treatment of acute myocardial infarction in haemodynamically stable patients, defined as patients who are not in cardiogenic shock and who have a systolic blood pressure greater than 100mmhg. lisinopril may be initiated within 24 hours of an acute myocardial infarction.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - lisinopril dihydrate, quantity: 10.89 mg - tablet - excipient ingredients: mannitol; iron oxide red; maize starch; magnesium stearate; calcium hydrogen phosphate dihydrate; croscarmellose sodium - 1.hypertension: lisinopril is indicated for the treatment of hypertension. it may be used alone or concomitantly with other classes of antihypertensive agents. sufficient data have not been provided to support the use of lisinopril in severe hypertension or renovascular hypertension. 2. congestive heart failure: lisinopril is also indicated for the treatment of heart failure. in such patients, it is recommended that lisinopril be administered together with a diuretic. 3. acute myocardial infarction: lisinopril is indicated for the treatment of acute myocardial infarction in haemodynamically stable patients, defined as patients who are not in cardiogenic shock and who have a systolic blood pressure greater than 100mmhg. lisinopril may be initiated within 24 hours of an acute myocardial infarction.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - lisinopril dihydrate, quantity: 5.44 mg - tablet - excipient ingredients: calcium hydrogen phosphate dihydrate; mannitol; maize starch; magnesium stearate; croscarmellose sodium; iron oxide red - 1.hypertension: lisinopril is indicated for the treatment of hypertension. it may be used alone or concomitantly with other classes of antihypertensive agents. sufficient data have not been provided to support the use of lisinopril in severe hypertension or renovascular hypertension. 2. congestive heart failure: lisinopril is also indicated for the treatment of heart failure. in such patients, it is recommended that lisinopril be administered together with a diuretic. 3. acute myocardial infarction: lisinopril is indicated for the treatment of acute myocardial infarction in haemodynamically stable patients, defined as patients who are not in cardiogenic shock and who have a systolic blood pressure greater than 100mmhg. lisinopril may be initiated within 24 hours of an acute myocardial infarction.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - fosinopril sodium, quantity: 20 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; sodium starch glycollate; pregelatinised maize starch; hyprolose; crospovidone; glyceryl behenate - monace is indicated for the treatment of mild to moderate hypertension. monace is effective alone as initial therapy or in combination with other antihypertensive agents. the antihypertensive effects of monace and diuretics used concomitantly are approximately additive. data have not been provided to support the use of monace in severe or renovascular hypertension. heart failure: monace is indicated for the management of heart failure when added to conventional therapy, including diuretics.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - fosinopril sodium, quantity: 10 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; sodium starch glycollate; pregelatinised maize starch; hyprolose; crospovidone; glyceryl behenate - monace is indicated for the treatment of mild to moderate hypertension. monace is effective alone as initial therapy or in combination with other antihypertensive agents. the antihypertensive effects of monace and diuretics used concomitantly are approximately additive. data have not been provided to support the use of monace in severe or renovascular hypertension. heart failure: monace is indicated for the management of heart failure when added to conventional therapy, including diuretics.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - fosinopril sodium, quantity: 20 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; lactose monohydrate; crospovidone; povidone; glyceryl behenate - hypertension: treatment of mild to moderate hypertension. fosinopril is effectine alone as initial therapy or in combination with other antihypertensive agents. the antihypertensive effects of fosinopril and diuretics used concomitantly are approximately additive. data have not been provided to support the use of fosinopril in severe or renovascular hypertension. heart failure: management of heart failure when added to conventional therapy, including diuretics.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - fosinopril sodium, quantity: 10 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; lactose monohydrate; crospovidone; povidone; glyceryl behenate - hypertension: treatment of mild to moderate hypertension. fosinopril is effectine alone as initial therapy or in combination with other antihypertensive agents. the antihypertensive effects of fosinopril and diuretics used concomitantly are approximately additive. data have not been provided to support the use of fosinopril in severe or renovascular hypertension. heart failure: management of heart failure when added to conventional therapy, including diuretics.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - captopril, quantity: 5 mg/ml - oral liquid, solution - excipient ingredients: sodium benzoate; hydrochloric acid; sodium hydroxide; sodium citrate dihydrate; disodium edetate; purified water; citric acid - 1.hypertension: capoten (captopril) is indicated for the treatment of hypertension. in using capoten, consideration should be given to the risk of neutropenia/agranulocytosis (see precautions). capoten is effective alone and in combination with other antihypertensive agents, especially thiazide-type diuretics. the blood pressure lowering effects of captopril and thiazides are approximately additive. 2. myocardial infarction: capoten is indicated to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction less than or equal to 40%, and to reduce the incidence of overt heart failure and subsequent hospitalisations for congestive heart failure in these patients. the efficacy data for the use of captopril following myocardial infarction are strongest for initiation of therapy beyond 3 days post-infarct. 3. heart failure: capoten (captopril) is indicated for the treatment of heart failure. in symptomatic patients it is recommended that capoten be administered together with a diuretic. 4. diabetic nephropathy: capoten is indicated for the treatment of diabetic nephropathy in patients with type 1 insulin- dependent diabetes mellitus.